AccuLine was founded with the vision of saving millions of lives worldwide by preventing the next heart attack. AccuLine is developing CORA – an accurate, non-invasive, and cost-effective exam for early detection of CAD. AccuLine's user-friendly exam includes a four-minute measurement of vital signs designed to replace inaccurate, time-consuming, and labor-intensive ergometry exams. This approach addresses the limitations of existing tools in accuracy, invasiveness, and cost. AccuLine has received grants from Google and the Israeli Innovation Authority, and among its shareholders are Mayo Clinic, eHealth Ventures and Maccabi Healthcare Services.